Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience

Suyash Mohan, Sanjeev Chawla, Sumei Wang, Gaurav Verma, Aaron Skolnik, Steven Brem, Katherine B. Peters, Harish Poptani

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Tumor-treating fields (TTFields) is a novel antimitotic treatment modality for patients with glioblastoma. To assess response to TTFields, a newly diagnosed patient with glioblastoma underwent diffusion, perfusion and 3D echo-planar spectroscopic imaging prior to initiation of TTFields plus temozolamide (baseline) and at 1- and 2-month follow-up periods. Increased mean diffusivity along with decreased fractional anisotropy and maximum relative cerebral blood volume were noted at 2 months relative to baseline suggesting inhibition of tumor growth and angiogenesis. Additionally, a reduction in choline/creatine was also noted during this period. These preliminary data indicate the potential of physiologic and metabolic MRI in assessing early treatment response to TTFields in combination with temozolamide.

Original languageEnglish
Pages (from-to)137-144
Number of pages8
JournalCNS oncology
Volume5
Issue number3
DOIs
StatePublished - 1 Jul 2016
Externally publishedYes

Keywords

  • diffusion tensor imaging
  • echo-planar spectroscopic imaging
  • glioblastoma
  • perfusion-weighted imaging
  • therapeutic response
  • tumor-treating fields

Fingerprint

Dive into the research topics of 'Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience'. Together they form a unique fingerprint.

Cite this